Michael Wyzga is President and Chief Executive Officer, and a member of the Board of Directors, of Radius. Prior to joining Radius, he was Executive Vice President, Finance and Chief Financial Officer of Genzyme until its acquisition by Sanofi in April 2011. Mr. Wyzga joined Genzyme in 1998 and held primary responsibility for the firm's financial management worldwide. He provided strategic leadership in the successful $20.1 billion sale of Genzyme to Sanofi, the second-largest acquisition in biotechnology history. Prior to joining Genzyme, Mr. Wyzga was Chief Financial Officer of Sovereign Hill Software. He previously served as Vice President of Finance and Chief Financial Officer of CacheLink Corporation, a client/service software company. Mr. Wyzga also held management positions at Lotus Development Corporation and Digital Equipment Corporation. He received an MBA from Providence College and a BS from Suffolk University.
Nick Harvey is Senior Vice President and Chief Financial Officer of Radius. He has more than 15 years of experience in building and financing life sciences and technology companies. Prior to joining Radius, he served for four years as Managing Director of Shiprock Capital, a venture capital firm, where he was responsible for deal-sourcing, negotiating and closing transactions, and developing strategic plans for portfolio companies. Before that, Mr. Harvey served as CFO of a number of venture-backed companies over a 10-year period, including Transfusion Technologies and Transcend Therapeutics. At Transfusion, he helped to close a major distribution agreement with Zimmer and oversaw the company's acquisition by Haemonetics. Mr. Harvey holds an undergraduate degree in Economics and a law degree with first-class honors from the Australian National University, and an MBA from the Harvard Business School.
Louis Brenner, MD, is Chief Medical officer of Radius. Prior to joining Radius, he served as Senior Vice President at AMAG Pharmaceuticals, where he was responsible for the Phase 3 studies and the successful regulatory submission for Feraheme®. Before that, he served in progressively senior roles at Genzyme, where he advanced the development and commercialization of products to treat metabolic bone disease.He is the co-inventor of the formulation for Renvela®, an oral phosphate binder to treat hyperphosphatemia, and lead the acquisition of Bone Care International, manufacturer of Hectorol®, a synthetic Vitamin D analog for the treatment of hyperparathyroidism. He also previously served as a Director of PLC Medical Systems. Dr. Brenner is board-certified in Nephrology and cares for patients at Brigham and Women's Hospital in Boston, and is a lecturer in Medicine at Harvard Medical School. He received a BS in Biology from Yale University, an MD from Duke University, and an MBA from Harvard Business School.
Michael Franken, MD, is Senior Vice President and Chief Business Officer of Radius. Prior to joining Radius, he served as Vice President and General Manager, Solid Organ Transplantation, at Genzyme Corporation, where he was successful in building and significantly growing the transplant business to more than $260 million in revenues through focused development of the transplant products (including Thymoglobuline®) across multiple indications and expanding commercial markets globally. Since joining Genzyme in 2000, Dr. Franken held progressively senior positions in corporate development, program, and general management. In the area of Immune Diseases and Fibrosis, he was responsible for the company's preclinical and clinical development portfolio and for business development, where he successfully identified and executed several licensing and partnering transactions. He also provided leadership in establishing and managing Genzyme Ventures, Genzyme's corporate venture capital arm. Prior to joining Genzyme, Dr. Franken was a life sciences business consultant at The Wilkerson Group. He received an MD from the University of Heidelberg, Germany and a Master in Health Policy and Management from Harvard University's School of Public Health.
Dr. Hattersley is Senior Vice President, Preclinical Development at Radius. He has more than 20 years of experience in musculoskeletal research and is the author of numerous scientific publications related to bone biology and physiology. Prior to joining Radius, Dr. Hattersley was a Senior Scientist at Millennium Pharmaceuticals with responsibility for the discovery and development of novel small-molecule agents for the treatment of osteoporosis and other metabolic bone diseases. Dr. Hattersley also held positions at Genetics Institute/Wyeth Research investigating the application of the bone morphogenetic proteins in bone and connective tissue repair and regeneration. Dr. Hattersley received a PhD in Experimental Pathology from St. George's Hospital Medical School in London.